Koya Medical

Executive Summary

Koya Medical is a privately held medical device company based in Oakland, California, dedicated to transforming the treatment of venous and lymphatic diseases, particularly chronic edema and related conditions. Founded in 2017, the company has developed the Dayspring system, a non-pneumatic, active compression therapy that offers a novel alternative to traditional pneumatic compression devices. Dayspring is designed to be wearable, silent, and mobile, enabling patients to receive effective compression therapy while maintaining daily activities. The system uses a unique, non-pneumatic mechanism that applies dynamic compression to improve lymphatic and venous flow without the bulk, noise, or immobility associated with existing solutions. This innovation addresses a significant unmet need in the management of lymphedema and chronic venous insufficiency, conditions affecting millions worldwide. Koya Medical has positioned itself to capture share in the growing vascular health market by offering a differentiated product that enhances patient compliance and quality of life. The company's progress has been marked by positive clinical outcomes and regulatory milestones. The Dayspring system has received FDA clearance for the treatment of lymphedema, and Koya is actively pursuing expanded indications and reimbursement coverage. With a strong intellectual property portfolio and a focus on patient-centric design, Koya Medical is poised to become a leader in active compression therapy. Key upcoming catalysts include the release of real-world evidence from ongoing post-market studies, potential expansion of FDA labeling to include chronic venous insufficiency, and strategic partnerships for distribution in international markets. The company's ability to execute on these catalysts will be critical to its growth trajectory and eventual exit opportunities.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for expanded indication in chronic venous insufficiency (CVI)75% success
• Q2 2026Publication of pivotal clinical trial results demonstrating superior efficacy vs. standard compression80% success
• Q4 2026First major commercial partnership or distribution agreement outside the U.S.65% success